- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Amgen, AstraZeneca report phase 3 results for Tezspire in eosinophilic esophagitis | 4 | Seeking Alpha | ||
| AMGEN INC CDR Aktie jetzt für 0€ handeln | |||||
| Di | Amgen und AstraZeneca melden positive Phase-3-Ergebnisse für Tezspire bei eosinophiler Ösophagitis | 13 | Investing.com Deutsch | ||
| Di | Amgen, AstraZeneca report positive trial results for Tezspire in EoE | 10 | Investing.com | ||
| Di | Amgen, AZ dive deep into Tezspire's Dupixent-challenging victory in EoE phase 3 | 4 | FiercePharma | ||
| 14.10. | Amgen springt nach Kursziel-News - was jetzt zählt | 32 | Maximilian Berger | ||
| 13.10. | Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy? | 51 | Insider Monkey | ||
| 08.10. | Cantor Fitzgerald raises Amgen stock price target on portfolio strength | 19 | Investing.com | ||
| 07.10. | Truist hebt Kursziel für Amgen auf 380 Dollar an - Pipeline im Fokus | 23 | Investing.com Deutsch | ||
| 05.10. | Cantor Fitzgerald reiterates Amgen stock Neutral rating at $400 | 17 | Investing.com | ||
| 03.10. | AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot | 22 | Seeking Alpha | ||
| 03.10. | David J. Taylor Purchases Amgen and Home Depot Stocks, Sells Marathon Petroleum | 28 | Investing.com | ||
| 02.10. | Ohio Rep. David Taylor Bought Up to $45K Worth of Amgen Stock | 5 | Benzinga.com | ||
| 30.09. | Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody | 7 | FierceBiotech | ||
| 29.09. | Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth? | 10 | Insider Monkey | ||
| 28.09. | Teva wins biosimilar approval of Amgen's Xgeva | 26 | Seeking Alpha | ||
| 23.09. | Natural Gas Key to Mexico's Energy Security: AMGN | 16 | Mexico Business News | ||
| 23.09. | Amgen's Horizon buyout delivers Sjögren's disease win | 3 | pharmaphorum | ||
| 23.09. | Canaccord reiterates Amgen stock Hold rating on pipeline win | 4 | Investing.com | ||
| 23.09. | Canaccord hält an 'Hold'-Rating für Amgen fest trotz Pipeline-Erfolg | 7 | Investing.com Deutsch | ||
| 23.09. | Oppenheimer reiterates Amgen stock rating on positive trial data | 6 | Investing.com |
1 2 3 4 5 Weiter >>
266 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,830 | +3,84 % | Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur | DJ Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur
DOW JONES--Der Finanzinvestor EQT will einem Agenturbericht zufolge den Diagnostikspezialisten Qiagen übernehmen. Wie... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 83,17 | 0,00 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 29,310 | -0,20 % | Guggenheim raises Rapport Therapeutics price target to $70 on trial data | ||
| PRAXIS PRECISION MEDICINES | 264,61 | +0,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,250 | 0,00 % | Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? | ||
| DISC MEDICINE | 79,45 | -0,04 % | Disc Medicine prices $450 million stock offering at $75/share | ||
| ARCUTIS BIOTHERAPEUTICS | 32,810 | 0,00 % | Arcutis BioTherapeutics advances 11% to new 52-week high | ||
| SUMMIT THERAPEUTICS | 16,095 | +0,03 % | Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca | LONDON (dpa-AFX) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of... ► Artikel lesen | |
| NURIX THERAPEUTICS | 26,130 | +0,11 % | H.C. Wainwright raises Nurix stock price target on strong revenue | ||
| MAZE THERAPEUTICS | 32,450 | 0,00 % | Canaccord stuft Maze Therapeutics mit "Buy" ein - Nierentherapien bieten hohes Kurspotenzial | ||
| ABSCI | 9,070 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen | |
| VERADERMICS | 127,66 | +0,34 % | Veradermics' hot streak continues with another phase 3 win in hair loss | ||
| RECURSION PHARMACEUTICALS | 3,665 | +0,14 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast | ||
| EDGEWISE THERAPEUTICS | 39,730 | -0,05 % | William Blair initiates Edgewise Therapeutics stock with outperform rating | ||
| IMMUNOME | 17,920 | 0,00 % | William Blair initiates Immunome stock coverage with outperform rating |
AMGEN INC CDR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 19,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AMGEN INC CDR finden Sie auf Wallstreet Online.